IP Library Granted Patent US 9,949,944
Granted Patent B2
US 9,949,944 · App. 14/801,944 · Granted Apr 24, 2018

Drug eluting expandable devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,949,944
App. No.
14/801,944
Granted
Apr 24, 2018
Kind
B2
Abstract

The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to coat the devices.

Claims (14)

1. A medical system comprising:

a stent; and

a drug eluting device comprising an expandable member coated with at least one layer

comprising an adjustable matrix composition comprising a sol gel material and a bioactive material;

wherein the expandable member has a plurality of expandable ribs that extend in a longitudinal direction to a flexible tip at one end and a sheath at a second end; and

wherein the expandable member is made of a polymer of at least one of polyamide, polyolefin, polyethylene, polyester, polyurethane, elastomer, thermoplastic elastomer, nylon elastomer, nylon, nylon blends, copolyamide block ether, polyether block amides (PEBAX), polyethylene terephthalate (PET), polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), latex, and silicone.

2. The medical system of claim 1 , wherein said stent is a bare metal stent or a drug eluting stent.

3. The medical system of claim 1 , further comprising a delivery catheter.

4. The medical system of claim 2 , wherein said drug eluting stent contains the same bioactive material as that of said drug eluting device.

5. The medical system of claim 2 , wherein said drug eluting stent contains a different bioactive material from that of said drug eluting device.

6. The medical system of claim 1 , wherein the at least one coating is deposited in a gradient over a length of the drug eluting device.

7. The medical system of claim 1 , wherein the bioactive material comprises at least one of an anti-restenotic agent, an anti-inflammatory agent, an HMG-CoA reductase inhibitor, an antimicrobial agent, an antineoplastic agent, an angiogenic agent, an anti-angiogenic agent, a thrombolytic agent, an antihypertensive agent, an anti-arrhythmic agent, a calcium channel blocker, a cholesterol-lowering agent, a psychoactive agent, an anti-depressive agent, an anti-seizure agent, a contraceptive, an analgesic, a bone growth factor, a bone remodeling factor, a neurotransmitter, a nucleic acid, an opiate antagonist; and combinations thereof.

8. The medical system of claim 1 , wherein the bioactive material comprises paclitaxel, rampamycin, everolimus, tacrolimus, sirolimus, des-aspartate angiotensin, nitric oxide, apocynin, gamma-tocopheryl, pleiotrophin, estradiol, aspirin, statin, atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and combinations thereof.

9. The medical system of claim 1 , wherein the at least one coating is two or more coating layers, wherein each layer is different.

Assignments (1)
SECURITY INTEREST Recorded Jul 31, 2017
From: CELONOVA BIOSCIENCES, INC.; CELONOVA STENT, INC.
To: CIP ADMINISTRATIVE, LLC
Reel/Frame 043382/0817 →